Haemonetics (HAE) fundamentals: P/E, valuation, undervalued?
Haemonetics · Health Care · ref. ETF XLV · price $105
In short — Haemonetics trades at 51.5× earnings (P/E), 18.3× forward, with a net margin of 7.1 % and revenue growth of +6 %. Read: High P/E (P/E 51 (above average)).
Is Haemonetics stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$105+93.2% over range
Aug 28, 25low $47.67 · high $108.8Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
71% recommend buying · 7 analysts
Valuation : High P/E — P/E 51 (above average)
Valuation
51.5
P/E (price/earnings)
18.3
Forward P/E
17.75
PEG
5.7
Price/book (P/B)
$4.8B
Market cap
2.04
EPS
Profitability & growth
7.1 %
Net margin
+6 %
Revenue growth
+3 %
Earnings growth
$1.2B
Total debt
Haemonetics income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $1.2B | $115M | 9.9 % |
| 2024 | $1.3B | $118M | 9.0 % |
| 2025 | $1.4B | $168M | 12.3 % |
| 2026 | $1.3B | $97M | 7.3 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Haemonetics's P/E and is the stock undervalued? What's a good P/E?
Haemonetics's P/E is 51.5 (forward 18.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Haemonetics profitable?
Haemonetics has a net margin of 7.1 % (EPS 2.04). The company is profitable.
Is HAE stock expensive?
Our read: "High P/E" — P/E 51 (above average). Cross-check with growth and sector.
💬 A question about Haemonetics? The JPI assistant answers using our backtest data.
Keep exploring Haemonetics